Ken Griffin Larimar Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$6.3 - $10.68 $78,120 - $132,432	-12,400 Reduced 33.97%	24,100 $157,000
Q2 2024 Aug 14, 2024	SELL	$6.33 - $9.89 $457,026 - $714,058	-72,200 Reduced 66.42%	36,500 $264,000
Q1 2024 May 15, 2024	BUY	$4.2 - $13.28 $446,880 - $1.41 Million	106,400 Added 4626.09%	108,700 $825,000
Q4 2023 Feb 14, 2024	SELL	$2.35 - $4.71 $4,935 - $9,891	-2,100 Reduced 47.73%	2,300 $10,000
Q3 2023 Nov 14, 2023	BUY	$3.08 - $4.49 $6,776 - $9,878	2,200 Added 100.0%	4,400 $17,000
Q2 2023 Aug 14, 2023	BUY	$3.13 - $5.27 $6,886 - $11,593	2,200 New	2,200 $6,000
Q4 2022 Feb 14, 2023	BUY	$2.73 - $5.08 $273 - $508	100 New	100 $0

128

67.3M

280K

76.3K

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $165M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.